Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.300 +0.400 (+44.44%)
Official Closing Price Updated: 4:15 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Century Reports Flat Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Monday's after hours session: top gainers and losers ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
4 Analysts Have This To Say About Century Therapeutics ↗
 
Via Benzinga
News headline image
5 Analysts Assess Century Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Century Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Recap: Century Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Century Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Century Therapeutics ↗
 
Via Benzinga
News headline image
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024 ↗
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing ↗
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
News headline image
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Century Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Where Century Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024 ↗
While not on everyone’s radar, these enticing entities just might deliver the goods. 
Via InvestorPlace
News headline image
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data ↗
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these... 
Via Benzinga
News headline image
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
News headline image
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential ↗
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler. 
Via InvestorPlace
News headline image
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach ↗
Why Are Gamma-Delta T Cells Important In Fighting Cancer? 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗
 
Via Benzinga
News headline image
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares... 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.